Adaptive Biotechnologies - Crunchbase Company Profile & Funding

Q: Who invested in Adaptive Biotechnologies?

Adaptive Biotechnologies has 10 investors including OrbiMed And ARK Investment Management.

Q: How much funding has Adaptive Biotechnologies raised to date?

Adaptive Biotechnologies has raised obfuscated.

Overview

Adaptive Biotechnologies

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Adaptive Biotechnologies

CB Rank

13713

Adaptive Biotechnologies translates scale and precision of the adaptive immune system into products to diagnose and treat disease.

Founded

obfuscation

Public

Post-IPO Debt

Seattle, Washington, United States

501-1000

adaptivebiotech.com

Biotechnology

Health Care

Therapeutics

Funding Rounds

Post-IPO Debt

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Key People

Chad Robins: Co-Founder, President & CEO
Past Role: Pulte Homes, Vice President of Operations
Julie Rubinstein: President
Past Role: Johnson & Johnson, Team Member

Details

Legal Name

Adaptive Biotechnologies Corporation

Also Known As

Adaptive TCR

Operating Status

Active

Stock Symbol

NASDAQ:ADPT

Company Type

For Profit

Founders

Chad Robins, Christopher Carlson, Harlan Robins

About the Company

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual

disease in patients with select blood cancers.

It was founded in 2009 and headquartered in Seattle, Washington.

Phone Number

(206) 659-0067

Contact Email

info@adaptivebiotech.com

Hub Tags

Exited Unicorn

Predictions & Insights

Growth Insight

See this Growth Insight

Adaptive Biotechnologies is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

clonoSEQ® Minimal Residual Disease (MRD) Testing

A next-generation sequencing (NGS)-based clinical test that detects and quantifies minimal residual disease in blood cancers for clinical practice and drug trials.

Adaptive Immunosequencing

A multiplex PCR-based assay and bioinformatics platform that sequences T- and B-cell receptors from genomic DNA to quantitatively profile the adaptive immune repertoire.

Research & Development

Adaptive Biotechnologies is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Adaptive Biotechnologies	—	obfuscated obfuscation	—	Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
OrbiMed	Yes	Post-IPO Debt - Adaptive Biotechnologies	Matthew S. Rizzo
OrbiMed	Yes	Post-IPO Debt - Adaptive Biotechnologies	Matthew S. Rizzo
OrbiMed	Yes	Post-IPO Debt - Adaptive Biotechnologies	Matthew S. Rizzo
OrbiMed	Yes	Post-IPO Debt - Adaptive Biotechnologies	Matthew S. Rizzo
OrbiMed	Yes	Post-IPO Debt - Adaptive Biotechnologies	Matthew S. Rizzo